On January 3, 2023, Bradley L. Radoff and Michael Torok announced that they have reiterated their intent to vote against Sesen Bio, Inc.?s proposed merger with Carisma Therapeutics Inc. In the statement, Bradley L. Radoff and Michael Torok stated that after reviewing the amended merger terms disclosed last week, Bradley L. Radoff and Michael Torok remains firmly opposed to what they deem an illogical, value-destructive transaction. Bradley L. Radoff and Michael Torok contend that the Company?s stockholders would be far better off if the merger was terminated and the Company?s approximately $140 million in cash was efficiently returned to investors along with the contemplated contingent value right (CVR) instrument.